Mefloquine exerts anticancer activity in prostate cancer cells via ROS-mediated modulation of Akt, ERK, JNK and AMPK signaling

Oncology Letters

Volumn 5, Issue 5, 2013, Pages 1541-1545

  Yan, Kun Huang ^a   Yao, Chih Jung ^a,b   Hsiao, Chi Hao ^a   Lin, Ke Hsun ^a   Lin, Yung Wei ^a   Wen, Yu Ching ^a   Liu, Chung Chi ^a   Yan, Ming De ^a   Chuang, Shuang En ^c   Lai, Gi Ming ^a,b,c,d   Lee, Liang Ming ^a,e  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b School of Chinese Medicine   (Taiwan)

^c NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^d Wan Fang Hospital   (Taiwan)

^e TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Hyperpolarization; Mefloquine; Mitochondrial membrane potential; N acetyl cysteine; Prostate cancer; Reactive oxygen species

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; MEFLOQUINE; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; REACTIVE OXYGEN METABOLITE; STRESS ACTIVATED PROTEIN KINASE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL PROLIFERATION; CELL VIABILITY; COLONY FORMATION; CONTROLLED STUDY; ELISA READER; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; INTRACELLULAR SIGNALING; MITOCHONDRIAL MEMBRANE POTENTIAL; PROSTATE CANCER; PROTEIN PHOSPHORYLATION; WESTERN BLOTTING;

EID: 84875704553     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2013.1211     Document Type: Article

References (28)

1. Geng Y, Kohli L, Klocke BJ and Roth KA: Chloroquine-induced autophagic vacuole accumulation and cell death in glioma cells is p53 independent. Neuro Oncol 12: 473-481, 2010.
2. Sotelo J, Briceno E and López-González MA: Adding chloroquine to conventional treatment for glioblastoma multiforme: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 144: 337-343, 2006.
3. Briceño E, Reyes S and Sotelo J: Therapy of glioblastoma multiforme improved by the antimutagenic chloroquine. Neurosurg Focus 14: e3, 2003.
4. Taylor WR and White NJ: Antimalarial drug toxicity: a review. Drug Saf 27: 25-61, 2004.
5. Simpson JA, Price R, ter Kuile F, Teja-Isavatharm P, NostenF, Chongsuphajaisiddhi T, Looareesuwan S, Aarons L and WhiteNJ: Population pharmacokinetics of mefloquine in patients with acute falciparum malaria. Clin Pharmacol Ther 66: 472-484, 1999.
6. Kollaritsch H, Karbwang J, Wiedermann G, Mikolasek A, Na-Bangchang K and Wernsdorfer WH: Mefloquine concentration profiles during prophylactic dose regimens. Wien Klin Wochenschr 112: 441-447, 2000.
7. Krudsood S, Looareesuwan S, Wilairatama P, Leowattana W, Tangpukdee N, Chalermrut K, Ramanathan S, Navaratnam V, Olliaro P, Vaillant M, Kiechel JR and Taylor WR: Effect of artesunate and mefloquine in combination on the Fridericia corrected QT intervals in Plasmodium falciparum infected adults from Thailand. Trop Med Int Health 16: 458-465, 2011.
8. ter Kuile FO, Nosten F, Thieren M, Luxemburger C, Edstein MD, Chongsuphajaisiddhi T, Phaipun L, Webster HK and White NJ: High-dose mefloquine in the treatment of multidrug-resistant falciparum malaria. J Infect Dis 166: 1393-1400, 1992.
9. Isaacs WB, Carter BS and Ewing CM: Wild-type p53 suppresses growth of human prostate cancer cells containing mutant p53 alleles. Cancer Res 51: 4716-4720, 1991.
10. Gurova KV, Rokhlin OW, Budanov AV, Burdelya LG, ChumakovPM, Cohen MB and Gudkov AV: Cooperation of two mutant p53 alleles contributes to Fas resistance of prostate carcinoma cells. Cancer Res 63: 2905-2912, 2003.
11. Bajgelman MC and Strauss BE: The DU145 human prostate carcinoma cell line harbors a temperature-sensitive allele of p53. Prostate 66: 1455-1462, 2006.
12. Keepers YP, Pizao PE, Peters GJ, van Ark-Otte J, Winograd B and Pinedo HM: Comparison of the sulforhodamine B protein and tetrazolium (MTT) assays for in vitro chemosensitivity testing. Eur J Cancer 27: 897-900, 1991.
13. McArdle JJ, Sellin LC, Coakley KM, Potian JG and HognasonK: Mefloquine selectively increases asynchronous acetylcholine release from motor nerve terminals. Neuropharmacology 50: 345-353, 2006.
14. Rogalska A, Koceva-Chyla A and Jóźwiak Z: Aclarubicin-induced ROS generation and collapse of mitochondrial membrane potential in human cancer cell lines. Chem Biol Interact 176: 58-70, 2008.
15. Liu H, Jiang C, Xiong C and Ruan J: DEDC, a new flavonoid induces apoptosis via a ROS-dependent mechanism in human neuroblastoma SH-SY5Y cells. Toxicol In Vitro: 26: 16-23, 2012.
16. Lan A, Liao X, Mo L, Yang C, Yang Z, Wang X, Hu F, Chen P, Feng J, Zheng D and Xiao L: Hydrogen sulfide protects against chemical hypoxia-induced injury by inhibiting ROS-activated ERK1/2 and p38MAPK signaling pathways in PC12 cells. PLoS One 6: e25921, 2011.
17. Dow GS, Caridha D, Goldberg M, Wolf L, Koenig ML, YourickDL and Wang Z: Transcriptional profiling of mefloquine-induced disruption of calcium homeostasis in neurons in vitro. Genomics86: 539-550, 2005.
18. Chlenski A, Nakashiro K, Ketels KV, Korovaitseva GI and OyasuR: Androgen receptor expression in androgen-independent prostate cancer cell lines. Prostate 47: 66-75, 2001.
19. Robertson CL, Scafidi S, McKenna MC and Fiskum G: Mitochondrial mechanisms of cell death and neuroprotection in pediatric ischemic and traumatic brain injury. Exp Neurol 218: 371-380, 2009.
20. Berghe TV, Vanlangenakker N, Parthoens E, Deckers W, Devos M, Festjens N, Guerin CJ, Brunk UT, Declercq W and Vandenabeele P: Necroptosis, necrosis and secondary necrosis converge on similar cellular disintegration features. Cell Death Differ 17: 922-930, 2010.
21. Skulachev VP: Bioenergetic aspects of apoptosis, necrosis and mitoptosis. Apoptosis 11: 473-485, 2006.
22. Hood JE, Jenkins JW, Milatovic D, Rongzhu L and Aschner M: Mefloquine induces oxidative stress and neurodegeneration in primary rat cortical neurons. Neurotoxicology 31: 518-523, 2010.
23. Zheng Z, Chen H, Zhao H, Liu K, Luo D, Chen Y, Yang X, Gu Q and Xu X: Inhibition of JAK2/STAT3-mediated VEGF upregulation under high glucose conditions by PEDF through a mitochondrial ROS pathway in vitro. Invest Ophthalmol Vis Sci51: 64-71, 2010.
24. Choi K, Kim J, Kim GW and Choi C: Oxidative stress-induced necrotic cell death via mitochondria-dependent burst of reactive oxygen species. Curr Neurovasc Res 6: 213-222, 2009.
25. Di Stefano A, Frosali S, Leonini A, Ettorre A, Priora R, DiSimplicio FC and Di Simplicio P: GSH depletion, protein S-glutathionylation and mitochondrial transmembrane potential hyperpolarization are early events in initiation of cell death induced by a mixture of isothiazolinones in HL60 cells. Biochim Biophys Acta 1763: 214-225, 2006.
26. Venditti P, Di Stefano L and Di Meo S: Mitochondrial metabolism of reactive oxygen species. Mitochondrion: Jan 29, 2013 (Epub ahead of print).
27. Li ZY, Yang Y, Ming M and Liu B: Mitochondrial ROS generation for regulation of autophagic pathways in cancer. Biochem Biophys Res Commun 414: 5-8, 2011.
28. Wang S, Song P and Zou MH: AMP-activated protein kinase, stress responses and cardiovascular diseases. Clin Sci (Lond) 122: 555-573, 2012.